Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 15,098 as of Friday, Aug. 16, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,393 issues advancing vs. 1,555 declining with 92 unchanged. The Health Services industry currently sits down 0.6% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Parexel International Corporation ( PRXL), up 2.7%, Boston Scientific ( BSX), up 1.6%, Cigna ( CI), up 1.4% and Aetna ( AET), up 0.9%. On the negative front, top decliners within the industry include Edwards Life ( EW), down 2.0%, CareFusion ( CFN), down 1.1%, St Jude Medical ( STJ), down 1.1%, DaVita HealthCare Partners ( DVA), down 1.0% and Waters Corporation ( WAT), down 1.0%. TheStreet would like to highlight 4 stocks pushing the industry higher today: 4. Grifols ( GRFS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Grifols is up $0.40 (1.3%) to $31.95 on average volume. Thus far, 182,648 shares of Grifols exchanged hands as compared to its average daily volume of 461,000 shares. The stock has ranged in price between $31.14-$31.96 after having opened the day at $31.60 as compared to the previous trading day's close of $31.55. Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $10.8 billion and is part of the health care sector. Shares are up 21.4% year to date as of the close of trading on Thursday. Currently there are 3 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.